In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
News|Podcasts|October 2, 2026
ACT Brief: Proactive Trial Risk Management, Federal Infrastructure Modernization, Pediatric Heart Disease Treatment
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In
part five of her interview , Claire Riches, VP of clinical solutions at Citeline, explains how AI is shifting trial risk management from reactive to proactive. By enabling sponsors to pressure-test protocols and anticipate pivots before a single patient is enrolled, AI moves from problem-solving after failures to prevention through early scenario modeling and feasibility validation. The HHS Advanced Research Projects Agency for Health launched the SURPASS program alongside three complementary initiatives to modernize trial design and operations , addressing the reality that clinical development takes over a decade on average and costs up to $2 billion. SURPASS combines adaptive platform design, real-time analytics, and operational automation, while companion programs expand site capacity through AI-enabled activation, build nationwide data infrastructure for regulatory-grade access, and give patients tools to contribute real-world data.- The
FDA approved an expanded indication for Camzyos for adolescent patients age 12 and older with symptomatic heart obstruction disease , marking the first disease-targeted therapy approved in this pediatric population and the broadest indication of any cardiac myosin inhibitor. The Phase III Scout-HCM trial enrolled 44 adolescents and showed the therapy reduced obstruction measurements by 48 millimeters compared with just 1.8 millimeters for placebo, with no patients experiencing dangerous heart function decline.
That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scratch, and how real-world data and AI improve enrollment screening accuracy.
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy moves to community care, and why data harmonization is AI's primary bottleneck.
In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Cecilia Xi, PhD, VP of clinical and scientific affairs at Vivalink, about why defensible trial data depends on traceability, platform ownership, and device strategy long after a study ends.
In today's ACT Brief, we examine understanding the patient journey from end to end, whether decentralization reduces site burden or just shifts it, and why nine European drugmakers are sounding urgent alarms.
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
3
Where AI Leads in Trial Design—and Where Humans Still Need To
4
What an AI-Informed Approach Means for How Sponsors Think About Risk
5